This trial demonstrated that the coadministration of ACC inhibitors with DGAT2 inhibitors can exert anti-MASH effects while resolving the hypertriglyceridemia associated with ACC inhibition. The gene discussed is DGAT2; the disease is hypertriglyceridemia.